Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora

Frontiers in Microbiology

Microbiology

Jiming Zhang¹  Bicui Chen²  Jianfei Long²  Bin Wang³  Ling Li⁴  Xiaolin Liu⁵  Jingru Gong⁵  Huiping Lu⁵  Han Zhu⁵  Chao Liu⁶  Hongyan Ren⁶ 

[1] Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China;Shanghai Institute of Infectious Diseases and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, China;Department of Infectious Diseases, Jing’An Branch of Huashan Hospital, Fudan University, Shanghai, China;Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China;Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China;Department of Pharmacy, Jing’an District Central Hospital, Fudan University, Shanghai, China;Department of Pharmacy, Jing’an District Central Hospital, Fudan University, Shanghai, China;Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China;Shanghai Mobio Biomedical Technology Co., Ltd., Shanghai, China;

关键词: hepatitis B virus;    HBeAg;    HBsAg;    tenofovir alafenamide;    gut microbiota;   

DOI  :  10.3389/fmicb.2023.1232180

 received in 2023-05-31, accepted in 2023-08-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundSevere liver diseases, such as liver fibrosis, cirrhosis, and liver cancer, are mainly caused by hepatitis B virus (HBV). This study investigated the differences between gut microbiota in HBeAg-positive and negative groups of patients with chronic hepatitis B (CHB) and investigated the effect of tenofovir alafenamide (TAF) on gut microbiota.MethodsThis prospective study included patients with CHB not taking nucleoside antivirals (No-NAs group, n = 95) and those taking TAF (TAF group, n = 60). We divided CHB patients into two groups according to the HBeAg status of the subjects on the day of data collection. Phase 1 are HBeAg-negative patients and phase 2 are HBeAg-positive patients. We investigated the improvement of clinical symptoms by TAF, as well as differences in gut microbiota between different groups by 16S rRNA high-throughput sequencing.ResultsGut microbiota demonstrated significant differences between patients with HBeAg-positive and -negative CHB. Both the No-NAs and TAF Phase 2 subgroups demonstrated significantly increased microbiota richness and diversity, showing greater heterogeneity. Additionally, the Phase 2 subgroup exhibited a low abundance of pathways associated with glucose metabolism and amino acid metabolism. The TAF group demonstrated a significantly decreased HBV load, alanine aminotransferase, and aspartate aminotransferase and a significant increase in prealbumin compared with the No-NAs group. No significant difference was found in uric acid, creatinine, blood calcium, inorganic phosphorus, eGFR, and β2-microglobulin concentrations between the two groups. Additionally, the urea level in the TAF group was significantly lower than that in the No-NAs group, but with no significant effect on other indicators such as eGFR and β2-microglobulin.ConclusionThis study revealed significant differences in gut microbiota composition and function between patients with HBeAg-positive and -negative CHB.

【 授权许可】

Unknown   
Copyright © 2023 Long, Gong, Zhu, Liu, Li, Chen, Ren, Liu, Lu, Zhang and Wang.